Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150781 | 0.94 | HTR2A (0.37) | TP53GAAPARP10LMNACHRM4 | |
| SCHEMBL4411316 | 0.88 | RORC (0.35) | TP53PARP10LMNA | |
| SCHEMBL4407001 | 0.87 | GAA (0.35) | TP53GAAPARP10LMNAPARP14 | |
| SCHEMBL4412034 | 0.87 | LMNA (0.40) | LMNA | |
| SCHEMBL4405326 | 0.85 | PDK1 (0.41) | GAALMNA | |
| SCHEMBL4404630 | 0.84 | LMNA (0.38) | TP53LMNA | |
| SCHEMBL4398557 | 0.84 | LMNA (0.38) | LMNACHRM4 | |
| SCHEMBL4398222 | 0.83 | LSS (0.40) | — | |
| SCHEMBL4403834 | 0.83 | LMNA (0.39) | LMNA | |
| SCHEMBL4396163 | 0.83 | CHRM2 (0.39) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-6916850-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-6900218-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| US-20030013846-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013656-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013847-A1 | Cytoprotective agents | MONSANTO TECHNOLOGY LLC | 2003-01-16 | — | — | US | disclosed |
| US-20030013657-A1 | Pyruvate derivatives | MONSANTO TECHNOLOGY, LLC. | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013847-A1 | Cytoprotective agents | PC, PDK1, PDK2 | TP53 951/4885GAA 622/4885PARP10 935/4885 |
| US-20030013657-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | TP53 1277/4885GAA 699/4885PARP10 1050/4885 |
| US-20030013846-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | TP53 1277/4885GAA 699/4885PARP10 1050/4885 |
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | TP53 4261/4885GAA 40/4885PARP10 1533/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | TP53 4261/4885GAA 40/4885PARP10 1533/4885 |
| US-20030013656-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | TP53 1277/4885GAA 699/4885PARP10 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.